Skip to main content
Premium Trial:

Request an Annual Quote

Cardiogenic Shock Assay From Sphingotec CE Marked

NEW YORK – Sphingotec announced its in vitro diagnostic assay for dipeptidyl peptidase 3 has been CE-IVD marked.

The company has launched the test.

According to the German diagnostic company, the assay, called IB10 Sphingotec DPP3, is the first CE-IVD-marked point-of-care biomarker test that can quantify DPP3 blood plasma levels. DPP3 is a biomarker that can predict outcomes in patients with cardiogenic shock when they are admitted to hospital intensive care units.

Sphingotec will make its test available initially to the critical care community "for further assessment of the clinical utility of the DPP3 biomarker in critical care settings." The test has been designed and validated for use on Sphingotec's fully automated Nexus IB10 whole blood point-of-care platform.